Browse the evidence

The rapid improvement in fasting plasma glucose induced by caloric restriction is closely correlated with a reduction in basal hepatic glucose output (HGO), suggesting that restraining HGO is a major mechanism of action.

Reducing caloric intake works partly by telling the liver to stop producing so much sugar. This metabolic shift happens quickly, often before significant fat loss occurs.

Dietary weight loss via a hypocaloric DASH-based diet significantly reduces sympathetic nervous system (SNS) activity (norepinephrine spillover and muscle sympathetic nerve activity) and improves cardiac baroreflex sensitivity in subjects with metabolic syndrome.

For individuals with metabolic syndrome, a structured weight loss program using a modified DASH diet (moderate fat, higher protein, low sodium) for 12 weeks can significantly reduce harmful sympathetic nervous system activity and improve heart health markers. This approach targets the root metabolic drivers (insulin resistance and leptin levels) rather than just weight, offering cardiovascular protection beyond simple fat loss.

Insulin-resistant subjects experience a significant reduction in whole-body norepinephrine spillover after weight loss, whereas insulin-sensitive subjects do not, despite similar weight loss amounts.

If you have metabolic syndrome and are insulin resistant, weight loss is particularly effective at calming your nervous system's stress response. If you are already insulin sensitive, weight loss still helps other metabolic markers, but may not lower sympathetic nerve activity as dramatically.

The 5:2 diet improves liver stiffness (a marker of fibrosis/inflammation) and reduces LDL cholesterol, whereas LCHF does not improve liver stiffness and may increase LDL.

If you have high cholesterol or heart disease risk, the 5:2 diet might be a better choice than LCHF because it lowers LDL and improves liver stiffness. LCHF reduces liver fat just as well but may not help with stiffness or cholesterol as much.

Intermittent fasting significantly increases adiponectin and decreases leptin levels, which may contribute to improved insulin sensitivity independent of significant fat mass loss.

Fasting may improve your metabolic health markers (like adiponectin) even if the scale doesn't move much, suggesting benefits beyond just weight loss.

A ketogenic diet is more effective than low-fat diets for improving glycemic control (HbA1c and HOMA-IR) in patients with type 2 diabetes, but shows comparable effects in non-diabetic patients.

If you have type 2 diabetes and are overweight, switching to a ketogenic diet (very low carb, high fat) is likely to improve your blood sugar control more effectively than a standard low-fat diet. If you do not have diabetes, the blood sugar benefits are similar to low-fat diets, though weight loss may still be superior.

Intermittent energy restriction (IER) significantly reduces fasting insulin levels compared to continuous energy restriction (CER), although the clinical relevance is uncertain.

IER may offer a slight advantage in lowering fasting insulin compared to daily restriction, which could be beneficial for metabolic health. However, since weight loss is the same, do not expect dramatic changes in body composition solely from this hormonal shift.

Reducing the intake of specific amino acids, particularly leucine and histidine, which are abundant in animal proteins, is associated with decreased fat mass and improved insulin resistance independent of total caloric intake.

Focus on the source of your protein. Plant proteins are naturally lower in leucine and histidine compared to animal proteins. This specific amino acid profile may help improve insulin sensitivity and reduce fat mass, even if total protein intake is adequate.

Achieving and maintaining diabetes remission (HbA1c <48 mmol/mol off glucose-lowering medications) is associated with a significantly lower incidence of Major Adverse Diabetic Events (MADE) compared to those not in remission.

Achieving diabetes remission is not just about feeling better; it actively protects your kidneys, eyes, and nerves from long-term damage. By maintaining remission through weight loss and lifestyle changes, you significantly lower your risk of serious diabetic complications.

Newer GLP-1 receptor agonists (semaglutide) and dual agonists (tirzepatide) significantly outperform older medications and lifestyle interventions alone, achieving weight losses of 12-17%.

Newer injectable medications like semaglutide (2.4mg weekly) and tirzepatide are significantly more effective than older drugs, achieving 12-17% weight loss. They represent a major step forward in pharmacotherapy for obesity.

A ketogenic diet significantly reduces HbA1c levels in overweight T2DM patients, though it does not significantly affect fasting glucose, fasting insulin, or HOMA-IR compared to control diets.

While a ketogenic diet effectively lowers long-term average blood sugar (HbA1c) in T2DM patients, it may not immediately change fasting blood glucose or insulin resistance scores (HOMA-IR) compared to other diets. This suggests the benefit is in sustained glucose regulation rather than acute fasting metrics.

A 6-week very-low-calorie diet (VLCD) significantly reduces hepatic free fatty acid (FFA) uptake and endogenous glucose production, thereby improving hepatic insulin sensitivity and fractional insulin extraction in obese individuals.

If you have significant liver fat and insulin resistance, a short-term (6-week) very-low-calorie diet (around 550 kcal/day) can rapidly reduce liver fat and improve how your liver handles insulin. This is achieved by reducing the amount of fatty acids your liver takes up. This intervention is intense and should be medically supervised, but it offers a faster metabolic reset than gradual weight loss alone.

Genetic variants in GLP1R (rs6923761) and TCF7L2 (rs7903146) influence the response to liraglutide, with specific genotypes associated with greater reductions in body fat and weight.

If you are taking liraglutide, your genetic makeup might influence how much fat or weight you lose. Some genetic variants are linked to better outcomes with this drug. This is not a reason to start or stop treatment, but may help explain individual differences in response.

A ketogenic very-low-energy diet (VLED) induces a transient increase in subjective hunger and desire to eat during the first 3 weeks (up to 5% weight loss), despite the presence of ketosis, with appetite suppression only emerging after 10% weight loss.

If you start a ketogenic very-low-energy diet, expect your hunger to increase significantly during the first 3 weeks, even if you are in ketosis. This is a normal, transient phase. Do not mistake this hunger for the diet not working; appetite suppression typically emerges only after you have lost about 10% of your body weight. Preparing for this initial hunger spike can help you stick with the diet.

Upon refeeding (cessation of ketosis) after significant weight loss (10-17%) on a ketogenic diet, hunger feelings and active ghrelin (AG) concentrations increase significantly, potentially undermining long-term weight maintenance.

When you stop the ketogenic diet and return to normal eating, expect your hunger and ghrelin levels to rise significantly. This is a physiological response to losing ketosis and weight. To mitigate this, transition gradually to your maintenance diet rather than stopping abruptly, and be aware that your body will signal for more food.

In obese men with metabolic syndrome, short-term weight loss via a hypocaloric low-fat diet increases LDL apoB-100 catabolism, thereby lowering plasma LDL cholesterol concentrations.

For men with metabolic syndrome, losing weight through a calorie-restricted, low-fat diet improves heart health by speeding up how your body clears LDL cholesterol from your blood. While this might not raise your HDL numbers, the reduction in LDL is a significant benefit for cardiovascular risk.

Weight regain after initial loss is driven by a persistent reduction in total energy expenditure and an increase in hunger/satiety signals (hormonal changes).

Understand that your body fights weight loss. After losing weight, your metabolism slows and hunger hormones change permanently. This is why maintaining weight is harder than losing it. You must account for this biological shift in your long-term plan.

Rapid weight loss in obese women reduces resting metabolic rate (RMR) by approximately 9.4% and serum T3 by 46%, but the resulting RMR remains within the normal range of lean, non-obese individuals, meaning hypometabolism does not prevent further weight loss.

If you are struggling to lose weight on a low-calorie diet, do not assume your metabolism has slowed down so much that you cannot lose weight. Research shows that even after rapid weight loss, your metabolic rate remains within the normal range for lean people. The reason you are not losing weight is likely that you are underestimating how much you are eating, not that your body is burning too few calories.

Time-restricted feeding (TRF) improves insulin sensitivity and glycemic control (including reduced glucose variability and HbA1c) in individuals with overweight or obesity, independent of significant weight loss in some studies.

If you have insulin resistance or pre-diabetes, try shifting your eating window to end earlier in the evening (e.g., 8 PM) and start later in the morning (e.g., 4 PM). This timing aligns with your body's natural circadian rhythms, helping to lower blood sugar spikes and improve how your body uses insulin, even if the scale doesn't move dramatically.

Alternate-Day Fasting (ADF) improves insulin sensitivity (HOMA-IR) more than Continuous Energy Restriction (CER).

If you are using Alternate-Day Fasting, you may see improvements in insulin sensitivity that are not seen with standard calorie restriction. This is a potential metabolic benefit of ADF.

Semaglutide and Liraglutide reduce the risk of Major Adverse Cardiovascular Events (MACEs), whereas Naltrexone/Bupropion increases the risk of elevated blood pressure.

If you have obesity and cardiovascular risks, Semaglutide or Liraglutide are preferred because they reduce MACE risk. Avoid Naltrexone/Bupropion if you have hypertension, as it increases blood pressure risk.

Caloric restriction improves insulin sensitivity and reduces fasting insulin, but has a minor or non-significant impact on fasting glucose levels in balanced groups.

Caloric restriction lowers insulin levels, which improves insulin sensitivity. However, it may not significantly lower fasting blood glucose unless the study groups were balanced at baseline.

Time-restricted eating (TRE) significantly reduces diastolic blood pressure (DBP) in adults with obesity, but does not significantly affect systolic blood pressure (SBP).

If you have high blood pressure, TRE might help lower your diastolic (bottom) number, but don't expect it to significantly change your systolic (top) number. This is a secondary benefit to weight loss, not a primary treatment for hypertension.

Intermittent Fasting improves metabolic health markers, including insulin sensitivity, lipid profiles (reduced triglycerides and LDL), and blood pressure, independent of weight loss magnitude, through mechanisms involving ketone body production and hormonal regulation.

Beyond weight loss, IER can improve your blood lipids and blood pressure. This happens partly because your body switches to burning fat for fuel (ketones) during fasting periods, which improves insulin sensitivity and reduces inflammation. You do not need to lose a massive amount of weight to see these metabolic benefits.